Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(83%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
3
50%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Active, not recruiting5
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting583%
completed117%

Recent Activity

5 active trials
Showing 5 of 6
active_not_recruitingphase_3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

NCT04164199
active_not_recruitingphase_2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708
active_not_recruitingphase_2

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT06010303
active_not_recruitingphase_2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

NCT05909904
active_not_recruitingphase_1

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04164199Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Active Not Recruiting
NCT05635708Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active Not Recruiting
NCT06010303Phase 2

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT05909904Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT05609370Phase 1

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Active Not Recruiting
NCT04640545Phase 1

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6